argenx SE (NASDAQ:ARGX) Shares Purchased by Wealth Alliance

Wealth Alliance increased its position in argenx SE (NASDAQ:ARGX) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 628 shares of the company’s stock after acquiring an additional 29 shares during the period. Wealth Alliance’s holdings in argenx were worth $270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of argenx by 26.2% in the fourth quarter. Wellington Management Group LLP now owns 279,168 shares of the company’s stock worth $106,204,000 after acquiring an additional 57,956 shares during the period. Sectoral Asset Management Inc. grew its position in argenx by 717.2% during the 4th quarter. Sectoral Asset Management Inc. now owns 10,027 shares of the company’s stock worth $3,815,000 after purchasing an additional 8,800 shares during the period. Boxer Capital LLC raised its stake in shares of argenx by 88.2% during the 4th quarter. Boxer Capital LLC now owns 160,000 shares of the company’s stock valued at $60,869,000 after buying an additional 75,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of argenx by 9.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 47,583 shares of the company’s stock valued at $18,102,000 after buying an additional 3,967 shares during the period. Finally, Altitude Crest Partners Inc. acquired a new position in shares of argenx in the 4th quarter valued at about $11,223,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the subject of several recent research reports. Robert W. Baird lifted their price target on argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Bank of America reiterated a “buy” rating and issued a $607.00 target price (up from $535.00) on shares of argenx in a research note on Monday, June 24th. JPMorgan Chase & Co. increased their price target on shares of argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Deutsche Bank Aktiengesellschaft raised shares of argenx from a “hold” rating to a “buy” rating in a report on Thursday, July 25th. Finally, HC Wainwright increased their target price on shares of argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $547.74.

argenx Stock Down 0.6 %

argenx stock opened at $533.00 on Friday. The company has a fifty day simple moving average of $512.59 and a 200-day simple moving average of $432.45. The firm has a market capitalization of $31.68 billion, a price-to-earnings ratio of -94.17 and a beta of 0.62. argenx SE has a 52-week low of $327.73 and a 52-week high of $554.74.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The company had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. During the same quarter in the prior year, the company earned ($1.69) EPS. On average, research analysts anticipate that argenx SE will post -0.37 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.